Ketopharm

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ketopharm

Property Description
Active ingredient Ketorolac tromethamine
Form Tablet, injectable solution, nasal spray, ophthalmic solution
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common use Acute pain and inflammation
Origin Synthetic organic compound

What Type of Drug is Ketopharm and What is its Composition?

Ketopharm is a prescription-only medication classified within the Non-Steroidal Anti-Inflammatory Drug (NSAID) pharmacological class, used primarily for its strong pain-relieving effects. The drug's identity is centered on its active ingredient, which is Ketorolac tromethamine. This substance is a synthetic organic compound, structurally belonging to the distinct pyrrolo-pyrrole group of NSAIDs. As a single active ingredient product, Ketopharm is defined by the Ketorolac component, whose pharmacological activity is carried by its (S)-(-) enantiomer, contributing to its high potency compared to common over-the-counter anti-inflammatories.

Forms of Ketorolac and General Therapeutic Purpose

Ketorolac is made available in multiple dosage form(s) to ensure flexible delivery, including an oral tablet, a sterile injectable solution, a specialized nasal spray, and an ophthalmic solution (drops). The general therapeutic purpose of Ketopharm is to serve as a powerful analgesic and anti-inflammatory agent for the short-term management of acute, moderately severe pain. This effectiveness is achieved because the drug acts as a non-selective COX inhibitor, performing prostaglandin synthesis inhibition to block the natural chemical messengers responsible for triggering pain and inflammation. Ketorolac is utilized for pain management when non-opioid options are preferred. Its high efficacy is clinically recognized for its ability to function as a valuable opioid sparing agent in acute care, a differentiating factor from less potent, general-purpose NSAIDs.

What side effects are possible with Ketopharm?

Possible Side Effects and Safety Information

Ketopharm is associated with a safety profile typical of Nonsteroidal Anti-inflammatory Drugs (NSAIDs), characterized by the potential for both common, generally mild adverse reactions and rare, but serious, organ-system toxicities.

Adverse Reactions

Common Adverse Reactions: The most frequently reported effects are generally mild and transient, primarily involving the Gastrointestinal (GI) tract (e.g., nausea, vomiting, heartburn, diarrhea, abdominal pain), Nervous System (e.g., headache, dizziness, visual disturbances), and Skin (e.g., rash, hypersensitivity reactions).

Serious Adverse Reactions: Regulatory data highlights the risk of severe complications, including gastric or duodenal ulceration that may lead to bleeding or perforation, acute renal failure, hepatitis, and pancreatitis. Life-threatening GI hemorrhage and severe renal injury have been reported in specific cases, emphasizing the need for caution, particularly with prolonged use.


Safety Considerations and Restrictions

Population-Specific Safety: Ketopharm is not recommended for use in the last trimester of pregnancy due to risks of premature closure of the fetal ductus arteriosus and potential to prolong labor. Use in pediatric patients (under 16 years old) is generally discouraged without medical supervision, as severe adverse reactions have been documented in adolescents. Risk of serious GI and renal events can be exacerbated by chronic use.

Restrictions for Use: To minimize safety risks, Ketopharm should not be used concurrently with any other analgesic or anti-pyretic medication. Use duration is formally restricted: no more than 3 days for fever and no more than 10 days for pain.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Ketorolac tromethamine is officially documented to often present with symptoms that are generally reversible. These clinical manifestations typically affect the gastrointestinal system and central nervous system, involving lethargy, drowsiness, nausea, vomiting, and epigastric pain.

Regulatory labeling warns of possible escalation to severe, rare outcomes such as acute renal failure, coma, respiratory depression, and significant gastrointestinal bleeding, including bloody or tarry stools. Immediate medical attention is mandated for any suspected overdose, especially if severe signs are present.

Management involves symptomatic and supportive care, as regulatory information explicitly states that no specific antidote is known for this medication. Procedures like gastric lavage, activated charcoal, and osmotic cathartics may be administered in specific scenarios, particularly following a documented large oral overdose (5 to 10 times the usual dose).

Immediate contact with emergency services or a poison control center is required if the individual has collapsed, has trouble breathing, or cannot be awakened. Regulatory documents note that elderly patients carry an increased risk for serious gastrointestinal events associated with overexposure.

Therapeutic Uses of Ketopharm

Ketopharm (Ketorolac) is commonly used for support for managing symptoms related to physical discomfort and inflammatory states in specific acute contexts. It is applied across domains where short-term symptomatic assistance is needed to manage symptoms related to physical discomfort and associated tissue reaction.

Ketorolac is used for managing symptoms of moderately severe pain, typically after surgery.


Key Therapeutic Domains and Benefits

This medication is applied in addressing conditions characterized by periods of heightened symptoms arising from postoperative recovery, acute traumatic injury, and managing the cluster of symptoms associated with acute inflammatory responses, including localized swelling and tissue irritation. For localized use, the drug is relevant for easing symptoms after cataract surgery and for pronounced ocular itching related to severe seasonal allergies.

“The drug is primarily relevant in contexts involving heightened systemic burden and provides symptomatic relief that helps patients cope more steadily.”

By moderating these distressing physical manifestations, the medication provides support that helps ease the overall symptom burden and assists with maintaining functional stability during symptomatic periods.

Quick Fact: Supports management of Acute Pain and Ocular Discomfort

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Ketopharm — Official Regulatory Information


Eligibility scope Populations for whom use is allowed (as stated in label): Adults 17 years and older are eligible for short-term use, limited to a maximum combined duration of five days. Populations for whom use is not recommended (if applicable): Use in patients with mild to moderate hepatic impairment should be approached with caution. Populations for whom use is contraindicated: Patients with active peptic ulcer disease, a history of GI bleeding or perforation, or known NSAID/aspirin hypersensitivity must not use this medicine. It is also prohibited for patients with advanced renal impairment, suspected or confirmed cerebrovascular bleeding, or those concurrently taking other NSAIDs. Age-related eligibility rules: Systemic use is not established for children under 17 years of age. Older adults (65 years and above) are designated as a population requiring extreme caution. Condition-specific eligibility rules: Severe renal impairment, severe hepatic failure, and severe heart failure define absolute non-eligibility. Pregnancy and lactation eligibility status (if explicitly documented): Use is absolutely contraindicated in the third trimester of pregnancy (at or after 30 weeks gestation), during labor and delivery, and in women who are breastfeeding. Eligibility-related restrictions: Use is contraindicated as prophylactic analgesia before major surgery or in the peri-operative setting of CABG surgery.


Eligibility classifications (high-level) Eligibility severity classification (as defined in official documents): Contraindicated (Absolute prohibition); Not Established (Pediatrics); Use with extreme caution (Older Adults). Regulatory basis (EMA / FDA / etc.): Prescribing Information; Summary of Product Characteristics; National Regulatory Monographs. Eligibility-context constraints (as defined in official documents): Short-term use only (maximum 5 days); Prohibited in states of critical hemostasis risk.


Resulting eligibility structure Official eligibility statements: • Use is Contraindicated in patients with a history of GI ulceration or bleeding and advanced renal impairment. • Use is Contraindicated in the third trimester of pregnancy and for breastfeeding women. • Systemic use is Not Established for children under 17 years of age.

Connection to the overall eligibility profile (2–4 sentences): Regulatory documentation strictly reserves Ketopharm for a limited adult population requiring short-term pain relief. The profile is primarily defined by numerous contraindications that exclude individuals presenting with high risks concerning gastrointestinal, renal, and hemorrhagic integrity. This rigorous approach ensures the medicine is administered only within the narrow population constraints established by government authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Co-administration of Ketopharm (Ketorolac tromethamine) is formally contraindicated with certain medicinal products, as strictly defined in regulatory labeling. These prohibited combinations include Aspirin and other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), due to the cumulative risk of severe NSAID-related adverse effects. The drug is also restricted for co-use with Probenecid, as this substance significantly decreases Ketorolac clearance, leading to elevated plasma concentrations. Regulatory labeling mandates that the total combined duration of use for all Ketorolac formulations must not exceed five days.

Interactions with Anticoagulants (such as Warfarin) and Antiplatelet Agents (including SSRIs) are officially documented to increase the risk of hemorrhage due to additive effects on hemostasis. The drug may also diminish the effects of Diuretics, ACE Inhibitors, and ARBs by interfering with renal prostaglandin synthesis. This interference may increase the risk of renal function deterioration, a consideration noted for elderly or volume-depleted patients.

Furthermore, Ketorolac affects the clearance of other medicines, leading to increased plasma levels and risk of toxicity when co-administered with Lithium and Methotrexate. The official label notes that Alcohol (Ethanol) may increase the risk of gastrointestinal bleeding.

Mechanism of Action

How Ketopharm Works: Mechanism of Action

Ketopharm operates via a dual pharmacodynamic mechanism, influencing both peripheral tissue signaling and central neural pathways. The primary action involves irreversible competitive inhibition of the Cyclooxygenase-2 (COX-2) enzyme. This binding blocks the enzyme's ability to catalyze the synthesis of pro-inflammatory mediators, specifically prostaglandins, within the Arachidonic Acid Cascade. Interrupting this molecular cascade reduces the local concentration of chemical activators, thereby influencing microvascular dynamics and nerve terminal sensitivity in peripheral tissues.

Simultaneously, a secondary mechanism involves the allosteric modulation of Serotonin-Norepinephrine Reuptake Transporters (SERT/NET) in the central nervous system. This interaction increases the effective concentration and residence time of Serotonin and Norepinephrine in the synaptic cleft. This action alters the activity patterns of monoaminergic pathways, which are involved in regulating central signal transmission and processing, resulting in modified nerve impulse transmission and an alteration in feedback mechanisms within these targeted pathways.

Dosage and Administration Information

How to Use Ketopharm: Administration Guidelines

Ketopharm (ketorolac tromethamine) is administered via several routes, including intravenous (IV) or intramuscular (IM) injection, oral tablet, intranasal spray, and a topical ophthalmic solution. The systemic administration (injection, tablet, or nasal spray) is governed by strict rules defining the total duration of use. The total combined duration of systemic therapy—regardless of the form—must not exceed five days.

Initial systemic therapy is typically administered via injection in a monitored setting. Standard adult IV/IM maintenance dosing is mathbf15 mg or mathbf30 mg administered mathbfevery 6 hours. The maximum recommended daily dose for most adults is mathbf120 mg. The oral tablet (mathbf10 mg) is used only as a continuation after initial injectable treatment, not as a starting dose, and is generally taken mathbfevery 4 to 6 hours.

Specific procedural and population-based constraints are established for clinical use. The IV dose must be administered slowly, over no less than 15 seconds. Furthermore, a reduced maximum daily dose (mathbf60 mg total) is required for older adults (mathbf65 years and older), patients under mathbf50 kg, or individuals with impaired kidney function. These constraints define the appropriate progression and limits for use.

Recent Clinical Evidence

Research evidence / Overview of studies for Ketopharm

Evidence for Short-Term Management of Moderately Severe Acute Pain

Research exploring the use of systemic Ketopharm (given by injection, oral tablet, or nasal spray) primarily involves short-term randomized controlled trials (RCTs). These studies were used in research exploring how outcomes related to physical discomfort change over time, especially when patients are dealing with conditions involving periods of heightened symptoms, such as immediately following surgery. Researchers examined various outcomes, including how patients reported their pain intensity on standardized scales and quantifying the use of other pain medications (opioids) required for rescue.

Findings describe patterns observed in the studies related to the use of other pain medications by groups receiving the drug when compared to those receiving a placebo or an inactive substance. Evidence is primarily focused on temporary, acute changes, and research does not determine whether an individual will respond similarly when symptoms are chronic or ongoing. There is limited information for long-term outcomes, as the evidence typically covers a treatment window of five days or less.

Evidence for Local Use Following Cataract Surgery

Studies exploring the use of the ophthalmic solution were primarily conducted using double-masked, vehicle-controlled clinical trials applied in research contexts involving patients who had recently undergone cataract extraction. The outcomes that studies monitored included measures of ocular pain intensity and clinical grades of inflammation inside the eye.

Research describes that in the observed populations, measurements of change in pain scores were reported in the days immediately following surgery compared to vehicle drops. Comparative evidence is limited when the ophthalmic solution was studied alongside other agents. The evidence base is specific to the immediate post-operative context, and research exploring short-term symptom changes typically provides limited information for long-term outcomes.

Research in Special Populations and Limitations

Ketopharm was studied for use in several specific groups to understand if group patterns were similar to the general adult population. Research examined cohorts of older adults (≥ 65 years) primarily for systemic use in managing acute pain, and explored outcomes related to patients with specific kidney function challenges. However, the data for pediatric patients remain insufficient, and certainty remains low regarding optimal use.

A key limitation is the established short-term window of the evidence. There is no comparable evidence for using the medicine for chronic or long-term painful conditions. Findings varied across studies in certain special groups, and research does not determine whether an individual will respond similarly to the group patterns observed in the trials.

Frequently Asked Questions (FAQ)

Common questions about Ketopharm (FAQ)


Q: Is Ketopharm similar to other medicines for the same condition?

According to official product information, Ketopharm is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). The drug belongs to the same pharmacological class as many common pain relievers. The active ingredient, Ketorolac tromethamine, is further described as belonging to the pyrrolo-pyrrole group of NSAIDs.


Q: Do the common side effects of Ketopharm tend to go away over time?

Regulatory documentation lists common adverse effects such as nausea, dizziness, and headache. While the common effects may be temporary, official information notes that if any symptoms become severe or do not go away, medical consultation is necessary.


Q: Can Ketopharm be taken with common over-the-counter pain relievers?

Official regulatory labeling formally states that Ketopharm is contraindicated (prohibited) for use with Aspirin and other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) due to the potential for an increased and cumulative risk of adverse effects associated with this drug class.


Q: Why do official documents state that Ketopharm should be used with caution in elderly patients?

Official documents indicate that patients 65 years and older require caution because they are at a greater risk for serious gastrointestinal events. Older adults may also experience a more pronounced occurrence of side effects, which is why a reduced maximum daily amount is generally indicated.


Q: Does Ketopharm interact with commonly used blood pressure medications?

Official information notes that Ketopharm may interact with certain blood pressure medications, including Diuretics, ACE Inhibitors, and ARBs. This interaction is described as potentially diminishing the effects of these medications by interfering with kidney function.


Q: Is there a documented interaction between Ketopharm and herbal supplements like St. John's Wort?

Official information advises informing a healthcare provider of all products being used, including herbal supplements, as some supplements may affect bleeding or organ function. Although not specifically named in contraindications, this general caution is appropriate due to the drug's known risks.


Q: Can Ketopharm cause drowsiness or affect my ability to drive?

Official regulatory documents list both dizziness and drowsiness as common adverse reactions. If these effects occur, it is noted that driving or operating machinery that requires mental alertness should be avoided.


Q: Can Ketopharm affect my sleep patterns or cause insomnia?

The official safety profile includes reports of insomnia, or difficulty sleeping, as an occasional adverse experience related to the nervous system.


Q: How is Ketopharm's safety profile described compared to placebo in clinical trials?

Research reports describe patterns suggesting that in clinical trials, groups receiving Ketopharm had a low incidence of side effects when compared to groups receiving an inactive substance (placebo).


Q: What happens if Ketopharm is taken alongside medications that also cause dizziness?

Dizziness is listed as a known adverse reaction of this medicine. Standard patient information notes that caution is appropriate when using Ketopharm alongside other medications that are known to cause similar side effects like dizziness or drowsiness.


Q: Are drug-drug interactions with Ketopharm categorized by severity (e.g., minor, moderate, major)?

The officially documented drug interactions are typically categorized by their level of clinical significance in medical reference texts. These categories include major (indicating the combination should be avoided), moderate (use with caution), and minor (minimize risk).


Q: Is there a patient information leaflet or guide for Ketopharm?

Regulatory authorities mandate that a Medication Guide or Patient Information Leaflet be made available to patients receiving the medicine. This document provides important safety and usage information.


Q: Does Ketopharm have a boxed warning, and what does it mean?

Yes, official regulatory labeling includes a prominent warning, sometimes called a Boxed Warning. This warning highlights the risk of serious side effects, including gastrointestinal bleeding, ulceration, and cardiovascular thrombotic events, such as heart attack or stroke.


Q: Are there any serious side effects associated with Ketopharm?

Official safety information highlights the potential for serious adverse reactions. These include severe gastrointestinal bleeding, ulceration, acute renal (kidney) failure, and serious cardiovascular events.


Q: How quickly can a person generally expect Ketopharm to start working?

Clinical information indicates that the pain-relieving effects of the drug generally begin within one hour of administration after systemic use.


Q: How long does the effect of a single dose of Ketopharm usually last?

Clinical studies indicate that the pain-relieving effect of a single systemic dose of the drug generally lasts for up to six to eight hours.


Q: What foods or beverages are described as having an interaction with Ketopharm?

Official information notes that taking the drug with a high-fat meal can slow down the speed at which the medicine is absorbed by the body.


Q: Does taking Ketopharm affect laboratory test results, like blood work?

Official documentation indicates that the drug may cause changes in certain laboratory tests. These include tests related to kidney and liver function, and it may also affect bleeding time.


Q: Is there a risk of vision changes or eye-related side effects with Ketopharm?

Official documentation lists visual disturbances, abnormal vision, and blurred vision as potential adverse reactions. This is noted in the safety profile for the systemic use of the drug.


Q: Do any official sources mention a risk of dependence or withdrawal with Ketopharm?

Regulatory labeling confirms Ketopharm is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). It is not classified as a controlled substance with a risk of dependence or withdrawal.


Q: Is it true that Ketopharm is broken down by the liver?

Regulatory information indicates that the drug is metabolized, or broken down, in the body, a process which occurs in the liver. The resulting inactive compounds are then mainly eliminated through the kidneys.


Q: How long after stopping Ketopharm does the drug usually leave the body?

Clinical information states that the average elimination half-life of Ketopharm is approximately 5 to 6 hours. Based on this, it generally takes less than two days for the drug to be considered fully eliminated from the body.

How should Ketopharm be stored and disposed of?

How to Store and Dispose of Ketorolac Tromethamine

The medication must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Tablets should be kept in the original, tightly closed container and protected from excess heat and moisture. The injectable solution must be protected from light and should not be refrigerated or frozen.

Child Safety and Stability

All forms of this medication must be stored out of the sight and reach of children. The injectable solution must be used immediately after opening, and any unused contents must be discarded.

Disposal Instructions

Unused or expired Ketorolac should be disposed of via an authorized drug take-back program. If this is unavailable, mix the medication (do not crush tablets) with an undesirable substance, seal it in a container, and place it in the household trash. Disposal of injection waste must follow local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ketopharm found in:

A-Z Index: